Plecanatide

Guanylate Cyclase-C Agonist — ALIMENTARY TRACT AND METABOLISM

Key facts

Plecanatide is a drug in the Guanylate Cyclase-C Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Guanylate Cyclase Activators. DrugCentral lists 4 molecular targets, including TNF, GUCY2C and TNFSF11. Recorded indications include Chronic idiopathic constipation.

• Drug class: Guanylate Cyclase-C Agonist.
• Mechanism of action: Guanylate Cyclase Activators.
• Molecular targets: TNF, GUCY2C, TNFSF11 and TNFRSF1A (4 listed in DrugCentral).
• Indications: Chronic idiopathic constipation.
• ATC code: A06AX07 (Other drugs for constipation).
• Molecular formula: C65H104N18O26S4; molecular weight 1681.89 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chronic idiopathic constipation

Mechanism & targets

• Mechanism of action (MoA): Guanylate Cyclase Activators
• Established pharmacologic class: Guanylate Cyclase-C Agonist

Molecular targets (4)

Target	Gene	Action	Activity
Tumor necrosis factor	TNF	unknown	Kd 8.42
Heat-stable enterotoxin receptor	GUCY2C	agonist	EC50 6.72
Tumor necrosis factor ligand superfamily member 11	TNFSF11	unknown	IC50 6.00
Tumor necrosis factor receptor superfamily member 1A	TNFRSF1A	unknown	IC50 4.66

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2017-01-19	FDA	—	SYNERGY PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
A06AX07	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Other drugs for constipation

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Diarrhoea	103.4
Abdominal distension	69.1
Flatulence	55.4
Product dose omission issue	41.4
Muscle spasms	34.4
Abdominal pain	33.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Plecanatide is on its molecule page.

• Molecular formula: C₆₅H₁₀₄N₁₈O₂₆S₄
• Molecular weight: 1681.89 g/mol
• CAS number: 467426-54-6
• InChIKey: NSPHQWLKCGGCQR-DLJDZFDSSA-N
• PubChem CID: 70693500

CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Plecanatide used for?

DrugCentral lists the following indications for Plecanatide: Chronic idiopathic constipation.

How does Plecanatide work?

Plecanatide is classified as Guanylate Cyclase Activators; its molecular targets in DrugCentral include TNF, GUCY2C (agonist), TNFSF11 and TNFRSF1A.

When was Plecanatide first approved?

Plecanatide was first approved by the FDA in 2017.

What drug class does Plecanatide belong to?

Plecanatide is in the Guanylate Cyclase-C Agonist class.

What is the chemical formula of Plecanatide?

Plecanatide has the molecular formula C65H104N18O26S4 and a molecular weight of 1681.89 g/mol.

Sources

• DrugCentral drug card 5208 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2103867 — compound record and bioactivity
• PubChem CID 70693500 — chemical identifiers
• DrugBank DB13170 — drug record
• FDA UNII 7IK8Z952OK — substance identity
• DailyMed: FDA labels for Plecanatide — current prescribing information (label search)
• UniProt P01375 (TNF) — target protein
• UniProt P25092 (GUCY2C) — target protein
• UniProt O14788 (TNFSF11) — target protein
• UniProt P19438 (TNFRSF1A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.